title: Emerging Therapies for Nonalcoholic Fatty Liver Disease.
abstract: Nonalcoholic fatty liver disease is the most common cause of liver disease in the United States. There are no drug therapies approved for the treatment of nonalcoholic steatohepatitis (NASH). Multiple different pathways are involved in the pathogenesis and each can be the target of the therapy. It is possible that more than 1 target is involved in disease development and progression. Multiple clinical trials with promising agents are underway. Because NASH is a slowly progressive disease and treatment likely to be of prolonged duration, acceptance and approval of any agent will require information on long-term clinical benefits and safety.
authors.affiliation: Division of Gastroenterology, University of California San Francisco S357, 513 Parnassus Avenue, San Francisco, CA 94143-0538, USA. Electronic address: Bilal.Hameed@ucsf.edu.
authors.forename: Bilal
authors.initials: B
authors.lastname: Hameed
authors.affiliation: Division of Gastroenterology, University of California San Francisco S357, 513 Parnassus Avenue, San Francisco, CA 94143-0538, USA.
authors.forename: Norah
authors.initials: N
authors.lastname: Terrault
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D061945:Caspase Inhibitors / Q000627:therapeutic use; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002793:Cholic Acids / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D006801:Humans; D054795:Incretins / Q000627:therapeutic use; D007333:Insulin Resistance; D000069450:Liraglutide / Q000627:therapeutic use; D000071518:Liver X Receptors / Q000037:antagonists & inhibitors; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000378:metabolism; D010368:Pectins / Q000627:therapeutic use; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000975:Antioxidants; D061945:Caspase Inhibitors; D002635:Chenodeoxycholic Acid; D002793:Cholic Acids; D015525:Fatty Acids, Omega-3; D054795:Incretins; D000069450:Liraglutide; D000071518:Liver X Receptors; D010368:Pectins; D047492:Peroxisome Proliferator-Activated Receptors; D018160:Receptors, Cytoplasmic and Nuclear; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000099150:Receptor, Farnesoid X-Activated; C089180:SLC5A2 protein, human; C464660:obeticholic acid; C000613471:simtuzumab; C000613472:belapectin; C455117:aramchol
keywords: Antifibrotic agents; FXR agonists; Insulin sensitizers; Nonalcoholic fatty liver disease; PPAR agonists